China Pharma Holdings (CPHI) Cash from Investing Activities (2010 - 2025)
China Pharma Holdings' (CPHI) quarterly Cash from Investing Activities came in at -$5767.0 in Q4 2025, up 97.89% YoY from -$2914.3 in Q4 2024, and up 85.79% on a QoQ basis from -$40598.0 in Q3 2025.
China Pharma Holdings (CPHI) Cash from Investing Activities (2010 - 2025) Analysis & Trends
China Pharma Holdings (CPHI) has 16 years of Cash from Investing Activities data on file, last reported at -$5767.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 97.89% year-over-year to -$5767.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$137251.0 (up 59.1% YoY) and the FY2025 annual result came in at -$137251.0, up 52.95% from the prior year.
- Cash from Investing Activities grew to -$5767.0 in Q4 2025, from -$40598.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $55964.0 in Q1 2023 to a low of -$415977.0 in Q3 2021.
- A 5-year average of -$77337.3 and a median of -$19809.0 in 2021 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 4123.29% — and 2024, when it plunged 5927.21%.
- Tracing CPHI's Cash from Investing Activities over 5 years: stood at -$7056.0 in 2021, then surged by 486.45% to $27268.0 in 2022, then slumped by 116.6% to -$4527.0 in 2023, then sank by 5927.21% to -$272852.0 in 2024, then soared by 97.89% to -$5767.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$5767.0 (Q4 2025), -$40598.0 (Q3 2025), and -$32562.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | China Pharma Holdings | 42.14 Mn | 41.84 Mn | 83,566.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5,767.00 |
| Dec 31, 2025 | -5,767.00 |
| Sep 30, 2025 | -40,598.00 |
| Sep 30, 2025 | -40,598.00 |
| Jun 30, 2025 | -32,562.00 |
| Jun 30, 2025 | -32,562.00 |
| Mar 31, 2025 | -58,324.00 |
| Mar 31, 2025 | -58,324.00 |
| Dec 31, 2024 | -272,852.00 |
| Dec 31, 2024 | -272,852.00 |
| Sep 30, 2024 | 9,220.00 |
| Sep 30, 2024 | 9,220.00 |
| Dec 31, 2023 | -4,527.00 |
| Dec 31, 2023 | -4,527.00 |
| Sep 30, 2023 | -67,455.00 |
| Sep 30, 2023 | -67,455.00 |
| Jun 30, 2023 | 4,501.00 |
| Jun 30, 2023 | 4,501.00 |
| Mar 31, 2023 | 55,964.00 |
| Mar 31, 2023 | 55,964.00 |